UBS Maintains Neutral on Incyte, Lowers Price Target to $94

Benzinga Newsdesk www.benzinga.com Negative 83.3%

Neg 83.3% Neu 0% Pos 0%

UBS analyst Ashwani Verma maintains Incyte (NASDAQ:INCY) with a Neutral and lowers the price target from $104 to $94.

Comments

No comments yet. Be the first!